CERo Therapeutics

CERo Therapeutics

  • Founded: 2017
  • Location: South SF, CA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: B-cell lymphoma
  • Drug types: ONC
  • Lead product: CER T cell
  • Product link: https://www.cero.bio/pipeline/
  • Funding: $40M A Mar 2020



job board

Short description:

Cellular Immunotherapy

Drug notes:

Also RD solid tumors; CER/CAR T-cell RD hematologic cancer, RD solid tumors

Long description:

CERo Therapeutics is developing cellular immunotherapies to create a new class of cancer therapeutics using recent insights from synthetic and T cell biology. Receptor mediated cell clearance is a method used daily by the body. CERo is creating chimeric engulfment receptor (CER) T cells, engineered T cells that recognize stress ligands found on the surface of tumor cells. Following recognition, the CER T cells are induced to kill the cancer cell and display tumor-associated antigens on their surface to further enhance the immune response. CERo’s first generation CER T cells are designed to recognise the phospholipid phosphatidylserine that is found on stressed cells. CERo’s platform also has the therapeutic potential to synergize with a variety of targeted therapies to improve patient outcomes.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com